Relevant bibliographies by topics / Fluoroquinolones

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Fluoroquinolones'

Author: Grafiati
Published: 4 June 2021
Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Fluoroquinolones.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Fluoroquinolones"

1

Tokura, Yoshiki, Naohiro Seo, Hiroaki Yagi, Fukumi Furukawa та Masahiro Takigawa. "Cross-Reactivity in Murine Fluoroquinolone Photoallergy: Exclusive Usage of TCR Vβ13 by Immune T Cells That Recognize Fluoroquinolone-Photomodified Cells". Journal of Immunology 160, № 8 (1998): 3719–28. http://dx.doi.org/10.4049/jimmunol.160.8.3719.

Full text
Abstract:
Abstract Fluoroquinolone antibacterial agents are well known to elicit photosensitivity as an adverse effect, and their cross-reactivity has been clinically documented. The photoallergenicity of fluoroquinolones is mainly derived from their photohaptenic moiety, and photomodification of skin epidermal cells with fluoroquinolones is thought to be an initial step for this photoallergy. Here we have explored, both in vivo and in vitro, T cell responses to fluoroquinolone-photomodified cells, focusing on their photoantigenic cross-reactivity. Cells were derivatized with fluoroquinolones under expo
APA, Harvard, Vancouver, ISO, and other styles
2

Pitman, Hoang, Wi, Alsheikh, Hiner, and Percival. "Revisiting Oral Fluoroquinolone and Multivalent Cation Drug-Drug Interactions: Are They Still Relevant?" Antibiotics 8, no. 3 (2019): 108. http://dx.doi.org/10.3390/antibiotics8030108.

Full text
Abstract:
Fluoroquinolones are a widely-prescribed, broad-spectrum class of antibiotics with several oral formulations notable for their high bioavailability. For certain infections, fluoroquinolones are the first line or only treatment choice. When administered orally, fluoroquinolones require proper administration to ensure adequate systemic absorption and, thereby, protect patients from treatment failure. Oral drug preparations that contain multivalent cations are well known to chelate with fluoroquinolones in the gastrointestinal tract; co-administration may lead to clinically significant decreases
APA, Harvard, Vancouver, ISO, and other styles
3

Macido, Antony. "An Umbrella Literature Review on Aortopathy and Fluoroquinolone Use." International Journal of Critical Care 18, no. 3 (2024): 51–67. http://dx.doi.org/10.29173/ijcc77.

Full text
Abstract:
Background: Aortic dissection and aortic rupture are critical vascular events often predisposed by aneurysmal dilation of the aorta. The use of fluoroquinolone has been associated with aortic dissection and aortic rupture, necessitating a careful clinical review before use. Despite black box warnings, fluoroquinolones continue to be one of the commonly prescribed antibiotics. Critical care providers, specifically those who work in close association with high-volume aortic centers, can play an active role in antibiotic stewardship in the use of fluoroquinolones in patients with a known or predi
APA, Harvard, Vancouver, ISO, and other styles
4

Patel, Samir N., Allison McGeer, Roberto Melano, et al. "Susceptibility ofStreptococcus pneumoniaeto Fluoroquinolones in Canada." Antimicrobial Agents and Chemotherapy 55, no. 8 (2011): 3703–8. http://dx.doi.org/10.1128/aac.00237-11.

Full text
Abstract:
ABSTRACTCiprofloxacin, the first fluoroquinolone to be used to treat lower respiratory tract infections (LRTI), demonstrates poor potency againstStreptococcus pneumoniae, and its use has been associated with the emergence of resistance. During the last decade, fluoroquinolones with enhancedin vitroactivity againstS. pneumoniaehave replaced ciprofloxacin for the treatment of LRTI. Here, we analyzed the impact of more active fluoroquinolone usage on pneumococci by examining the fluoroquinolone usage, prevalence of fluoroquinolone resistance, and mutations in the genes that encode the major targe
APA, Harvard, Vancouver, ISO, and other styles
5

Kopnova, T. Yu, L. R. Yakupova, I. M. Le-Deygen, and E. V. Kudryashova. "Influence of Physicochemical Properties of Fluoroquinolones on their Interaction with Human Serum Albumin." Biotekhnologiya 36, no. 6 (2020): 149–54. http://dx.doi.org/10.21519/0234-2758-2020-36-6-149-154.

Full text
Abstract:
It has been shown on the example of ciprofloxacin and levofloxacin that fluoroquinolones are able to interact with human serum albumin even at low molar ratios. A fivefold molar excess of fluoroquinolone quenched the protein fluorescence until its completely disappeared. The data of fluorescent analysis led to the conclusion that the relationship between the protein and hydrophobic ciprofloxacin is based on hydrophobic bonds, while less hydrophobic levofloxacin interacts with serum albumin via electrostatics. It was established that kinetics of drug release from the protein--fluoroquinolon com
APA, Harvard, Vancouver, ISO, and other styles
6

Bebear, C. M., H. Renaudin, A. Charron, D. Gruson, M. Lefrancois, and C. Bebear. "In Vitro Activity of Trovafloxacin Compared to Those of Five Antimicrobials against Mycoplasmas IncludingMycoplasma hominis and Ureaplasma urealyticumFluoroquinolone-Resistant Isolates That Have Been Genetically Characterized." Antimicrobial Agents and Chemotherapy 44, no. 9 (2000): 2557–60. http://dx.doi.org/10.1128/aac.44.9.2557-2560.2000.

Full text
Abstract:
ABSTRACT The in vitro activity of trovafloxacin against 125 strains ofMycoplasma species and Ureaplasma urealyticum, including fluoroquinolone-susceptible and fluoroquinolone-resistant species, was compared to those of other fluoroquinolones, doxycycline, and erythromycin. The MIC at which 90% of isolates are inhibited for all fluoroquinolone-susceptible strains was 0.25 μg/ml. Whatever the associated mutations, trovafloxacin exhibited greater activity than the other fluoroquinolones tested against fluoroquinolone-resistantMycoplasma hominis and U. urealyticum isolates.
APA, Harvard, Vancouver, ISO, and other styles
7

Kucharczyk, Emilia, Natalia Kucharczyk, and Karolina Pawłuszkiewicz. "Impact of Fluoroquinolones on Tendon Health: A Comprehensive Overview for the General Population and Athletes." Quality in Sport 31 (November 12, 2024): 55763. http://dx.doi.org/10.12775/qs.2024.31.55763.

Full text
Abstract:
Introduction: Fluoroquinolones are a class of broad-spectrum antibiotics widely used to treat various bacterial infections. Despite their effectiveness, increasing evidence links fluoroquinolones to tendinopathy and tendon rupture, with cases occurring shortly after initiation or even months post-therapy. This review provides a comprehensive overview of the impact of fluoroquinolones on tendon health - highlighting the underlying pathomechanisms, clinical manifestations, and epidemiology of fluoroquinolone-associated tendinopathy. Purpose of the work: The purpose of this study is to review the
APA, Harvard, Vancouver, ISO, and other styles
8

Murray, Hugh, Ee Laine Tay, Sarah Dinh, Helen Matthews, Alan Street, and Justin T. Denholm. "The Use of Fluoroquinolones for Tuberculosis in Victoria between 2011 and 2016." Tuberculosis Research and Treatment 2018 (July 2, 2018): 1–6. http://dx.doi.org/10.1155/2018/6860479.

Full text
Abstract:
Setting. Tuberculosis treatment requires long regimens with multiple antibiotics and is complicated by antibiotic resistance and intolerance. Fluoroquinolones were introduced for the treatment of multidrug resistant TB and have become a vital part of therapy. Objective. Reviewing the indications for fluoroquinolones use in the treatment of active TB in Victoria, Australia. Design. This was a retrospective case-control study of Victorian patients prescribed fluoroquinolones for active tuberculosis, from January 2011 to December 2016. Indications for fluoroquinolone use were extracted from an ex
APA, Harvard, Vancouver, ISO, and other styles
9

Becnel Boyd, Lauren, Merry J. Maynard, Sonia K. Morgan-Linnell, et al. "Relationships among Ciprofloxacin, Gatifloxacin, Levofloxacin, and Norfloxacin MICs for Fluoroquinolone-Resistant Escherichia coli Clinical Isolates." Antimicrobial Agents and Chemotherapy 53, no. 1 (2008): 229–34. http://dx.doi.org/10.1128/aac.00722-08.

Full text
Abstract:
ABSTRACT Fluoroquinolones are some of the most prescribed antibiotics in the United States. Previously, we and others showed that the fluoroquinolones exhibit a class effect with regard to the CLSI-established breakpoints for resistance, such that decreased susceptibility (i.e., an increased MIC) to one fluoroquinolone means a simultaneously decreased susceptibility to all. For defined strains, however, clear differences exist in the pharmacodynamic properties of each fluoroquinolone and the extent to which resistance-associated genotypes affect the MICs of each fluoroquinolone. In a pilot stu
APA, Harvard, Vancouver, ISO, and other styles
10

Leibovitz, Eugene. "The use of fluoroquinolones in children." Current Opinion in Pediatrics 18, no. 1 (2006): 64–70. https://doi.org/10.1097/01.mop.0001110952.28102.8f.

Full text
Abstract:
Abstract Purpose of review The fluoroquinolones are an important group of antibiotics widely used in the treatment of various infectious diseases in adults, as a result of an excellent spectrum of activity, good tissue penetration and convenient ways of administration. Their use in children is limited as a result of possible fluoroquinolone-induced joint/cartilage toxicity observed mainly in juvenile animal studies. Recent findings Fluoroquinolones were successfully used in immunocompromised children and also in those suffering from multidrug-resistant Gram-negative infections (including neona
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Fluoroquinolones"

1

Coffinier, Laurence. "Pharmacocinétique comparée des différentes fluoroquinolones à visée systémique." Paris 5, 1992. http://www.theses.fr/1992PA05P094.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Le, Guillou-Clemencin Claire. "Effets secondaires des fluoroquinolones : synthèse de deux nouvelles fluoroquinolones." Paris 5, 1994. http://www.theses.fr/1994PA05P256.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mathieu, Muriel. "Les effets indésirables des fluoroquinolones." Paris 5, 1996. http://www.theses.fr/1996PA05P116.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Soussy, Philippe-Julien. "Activité in vitro de la clinafloxacine, et comparaison à quatre autres fluoroquinolones." Paris 5, 1999. http://www.theses.fr/1999PA05P212.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Duval, Karine. "Phototoxicité des fluoroquinolones." Bordeaux 2, 1998. http://www.theses.fr/1998BOR2P010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

BLAISE, KLINGELSCHMITT ELISABETH. "Etude des fluoroquinolones : les fluoroquinolones actuellement disponibles et leurs utilisations therapeutiques." Université Louis Pasteur (Strasbourg) (1971-2008), 1990. http://www.theses.fr/1990STR15072.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lacour, Marie-Pierre. "Rupture tendineuse et fluoroquinolones." Bordeaux 2, 1991. http://www.theses.fr/1991BOR2M127.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

MARSEILLE, SOPHIE, and YANN LELONG. "Tendinopathies iatrogenes aux fluoroquinolones." Lille 2, 1997. http://www.theses.fr/1997LIL2P038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gueylard, Chenevier Delphine. "Passages transmembranaires des fluoroquinolones : étude in vitro des transferts intestinaux de l'ofloxacine." Paris 5, 1997. http://www.theses.fr/1997PA05P188.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Brunhes, Marie-Pierre Paille François. "Les effets indésirables des fluoroquinolones chez les sujets âgés de 65 ans et plus." [S.l.] : [s.n.], 2003. http://www.scd.uhp-nancy.fr/docnum/SCDMED_T_2003_BRUNHES_MARIE_PIERRE.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Fluoroquinolones"

1

C, Sanders Christine, ed. Fluoroquinolones in the treatment of infectious diseases. Physicians & Scientists Pub. Co., 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Read, Robert C. Clinician's manual on respiratory tract infections and fluoroquinolones. Science Press, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ricci, Vito. The accumulation of fluoroquinolones by bacteroides fragilis and the role of efflux and topoisomerase mutations in fluoroquinolone resistance. University of Birmingham, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jane, Metge Colleen, and Canadian Coordinating Office for Health Technology Assessment., eds. New fluoroquinolones in community-acquired pneumonia: A clinical and economic evaluation. Canadian Coordinating Office for Health Technology Assessment, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jane, Metge Colleen, and Canadian Coordinating Office for Health Technology Assessment., eds. New fluoroquinolones in community-acquired pneumonia: A clinical and economic evaluation. Canadian Coordinating Office for Health Technology Assessment, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Canadian Coordinating Office for Health Technology Assessment., ed. The new fluoroquinolones in community-acquired pneumonia: Clinical and economic perspectives. Canadian Coordinating Office for Health Technology Assessment, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ronald, Allan R., and Donald E. Low, eds. Fluoroquinolone Antibiotics. Birkhäuser Basel, 2003. http://dx.doi.org/10.1007/978-3-0348-8103-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

name, No. Fluoroquinolone antibiotics. Birkhauser, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

R, Ronald Allan, and Low Don E, eds. Fluoroquinolone antibiotics. Birkhäuser, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pieper, Stefan. Fluoroquinolone-Associated Disability FQAD. Springer Berlin Heidelberg, 2024. https://doi.org/10.1007/978-3-662-69763-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Fluoroquinolones"

1

Dimond, Renee, Rahul P. Patel, and Syed Tabish R. Zaidi. "Fluoroquinolones." In Drug Dosing in Obesity. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-44034-7_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bryskier, A. "Fluoroquinolones." In Antimicrobial Agents. ASM Press, 2014. http://dx.doi.org/10.1128/9781555815929.ch26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Champagne, Trevor. "Antibiotics, Fluoroquinolones." In Litt's Drug Eruption & Reaction Manual, 31st ed. CRC Press, 2025. https://doi.org/10.1201/9781003569756-1502.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Treves-Brown, K. M. "Quinolones and Fluoroquinolones." In Applied Fish Pharmacology. Springer Netherlands, 2000. http://dx.doi.org/10.1007/978-94-017-0761-9_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Elshaboury, Ramy H., Thomas J. Dilworth, and John C. Rotschafer. "Pharmacodynamics of Fluoroquinolones." In Methods in Pharmacology and Toxicology. Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3323-5_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dudley, Michael N. "Pharmacokinetics of Fluoroquinolones." In Quinolone Antimicrobial Agents. ASM Press, 2014. http://dx.doi.org/10.1128/9781555817817.ch6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Charushin, Valery N., Emiliya V. Nosova, Galina N. Lipunova, and Oleg N. Chupakhin. "Fluoroquinolones: Synthesis and Application." In Fluorine in Heterocyclic Chemistry Volume 2. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-04435-4_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ferguson, James. "Phototoxicity Due to Fluoroquinolones." In Quinolone Antimicrobial Agents. ASM Press, 2014. http://dx.doi.org/10.1128/9781555817817.ch28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Piddock, L. J. V. "Resistance to Quinolones and Fluoroquinolones." In Handbook of Experimental Pharmacology. Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-74095-4_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lecomte, S., M. T. Chenon, and M. H. Baron. "Mechanism of Activity of Fluoroquinolones." In Spectroscopy of Biological Molecules: Modern Trends. Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-011-5622-6_185.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Fluoroquinolones"

1

Le-Deygen, I. M., P. V. Mamaeva, A. S. Safronova, A. A. Skuredina, I. M. Kolmogorov, and E. V. Kudryashova. "CHEMICAL DESIGN OF DRUG DELIVERY SYSTEMS BASED ON LIPID-POLYMER CARRIERS ON THE EXAMPLE OF ANTIBACTERIAL AND ANTIFIBROTIC DRUGS." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-97.

Full text
Abstract:
Here we propose an approach to the chemical design of delivery systems for antifibrotic (pirfenidone, nintendanib) drugs and fluoroquinolones (levofloxacin, moxifloxacin) based on complexes of liposomal forms with polyelectrolytes using chitosan derivatives as an example. The systems have been extensively studied in silica and also tested in vivo when administered endotracheally to mice.
APA, Harvard, Vancouver, ISO, and other styles
2

Broussard, BA, AN Nguyen, SP Nishi, et al. "Effect of Fluoroquinolones on Development ofStenotrophomonas maltophiliaInfections in Lung Recipients." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a1740.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yi, Lina, Akio Aono, Kinuyo Chikamatsu, et al. "MIC andgyrA/Bgenetic analyses of fluoroquinolones againstmycobacterium tuberculosisisolated in Japan." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa1909.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hryhoriv, Halyna, Sergiy M. Kovalenko, Lyudmila Sidorenko, Natalia Filimonova, Lina Perekhoda, and Victoriya Georgiyants. "Hybridization of Fluoroquinolones as a Promising Pathway towards New Antibiotics." In ECMC 2022. MDPI, 2022. http://dx.doi.org/10.3390/ecmc2022-13145.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pirrone, A., M. Avantaggiato, and F. Panzeri. "5PSQ-002 Prescribing trend of fluoroquinolones following latest EMA recommendations." In 28th EAHP Congress, Bordeaux, France, 20-21-22 March 2024. British Medical Journal Publishing Group, 2024. http://dx.doi.org/10.1136/ejhpharm-2024-eahp.336.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Olivan, A., A. Autellet, I. Merhari, M. Carrot, G. Baroux, and G. Maquin. "5PSQ-107 Compliance of fluoroquinolones prescriptions: a hospital acquired resistance?" In 28th EAHP Congress, Bordeaux, France, 20-21-22 March 2024. British Medical Journal Publishing Group, 2024. http://dx.doi.org/10.1136/ejhpharm-2024-eahp.441.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Khokhlova, Yulia, Marina Gubkina, Natalya Yukhimenko, Irina Petrakova, and Svetlana Sterlikova. "Efficacy and safety of chemotherapy regimens containing fluoroquinolones in pediatric TB." In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa1720.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Moiseeva, A. A., V. N. ,. Skvortsov, and A. A. Prisnyi. "EFFECT OF ENROFLOXACIN ON WHITE BLOOD CELL DYNAMICS IN YOUNG POULTRY." In "International Scientific and Practical Conference" THEORY AND PRACTICE OF VETERINARY PHARMACY, ECOLOGY AND TOXICOLOGY IN AIC ", dedicated to the centenary of the Department of Pharmacology and Toxicology, SPbSUVM. FSBEI HE St. Petersburg SUVM, 2021. http://dx.doi.org/10.52419/3006-2021-2-168-170.

Full text
Abstract:
Analysis of hematological profile of poultry may serve as a tool for monitoring the impact of various medicinal drugs on the organism and for detection of their unknown effects. We studied the obtained blood parameters while bearing in mind our goal to extend knowledge of the impact of fluoroquinolones on the organism of different kinds of poultry in view of certain lack of such knowledge especially for poultry of young ages.
APA, Harvard, Vancouver, ISO, and other styles
9

Lavrenchuk, Leonid, Tatyana Umpeleva, Natalya Eremeeva, and Diana Vakhrusheva. "Genetic polymorphism and phenotypic resistance of Mycobacterium tuberculosis to fluoroquinolones of different generations." In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.oa4204.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ioannidou, Despoina, Areti Tychala, Eleni Faniadou, et al. "Comparative in vitro activity of fluoroquinolones against P. aeruginosa isolated from Greek CF patients." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.686.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Fluoroquinolones"

1

Parshikov, Igor A., and Evgeny I. Zaraisky. Bioconversions of Potentially Anti-tumor Fluoroquinolones. АНО «РИЭПСИ», 2018. http://dx.doi.org/10.18411/1995-4417n2_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

เฉลิมชัยกิจ, ธงชัย, จิโรจ ศศิปรียจันทร์ та มณฑล เลิศวรปรีชา. การเฝ้าระวังเชื้อแบคทีเรียเอนเตอร์โรค๊อคคัส และซาลโมเนลล่าที่ดื้อยาในไก่เนื้อ : รายงานผลการวิจัย. จุฬาลงกรณ์มหาวิทยาลัย, 2003. https://doi.org/10.58837/chula.res.2003.65.

Full text
Abstract:
จากการศึกษาในปี พ.ศ. 2545 โดยทำการตรวจตัวอย่างอุจจาระไก่พื้นเมือง (ไก่บ้าน) ของเกษตรกรรายย่อยที่เลี้ยงปล่อยในชนบทและตัวอย่างอุจจาระไก่เนื้อในฟาร์ม (ไก่ฟาร์ม) ที่เลี้ยงในระบบอุตสาหกรรมพบว่าความชุกของเชื้อซาลโมเนลล่าเท่ากับ 1 และ 5% ตามลำดับ โดยพบเชื้อซาลโมเนลล่าในตัวอย่างเนื้อไก่บ้าน ตัวอย่างเนื้อไก่จากซุปเปอร์มาร์เก็ตและจากตลาดสดเท่ากับ 13, 19 และ 64% ตามลำดับ ซึ่งซีโรวาร์ของเชื้อซาลโมเนลล่าที่พบในแต่ละกลุ่มตัวอย่างมีความหลากหลายแต่ซีโรวาร์ที่พบสูงถึง 43.5% ในตัวอย่างอุจจาระไก่ฟาร์ม คือ S. Enteritidis ส่วนในตัวอย่างเนื้อไก่จากซุปเปอร์มาร์เก็ตและจากตลาดสดพบว่าเป็น S. Enteritidis 16 และ 9.2% ตาม
APA, Harvard, Vancouver, ISO, and other styles
3

ฉัตรสุวรรณ, ธนิษฐา, วันทนา ปวีณกิตติพร та ผดุงศรี ดับส์. ฤทธิ์ของยาต้านจุลชีพที่ใช้ร่วมกันต่อเชื้อ Acinetobacter baumannii ที่ดื้อยาหลายขนานและความสัมพันธ์กับกลไกการดื้อยา : แนวทางในการรักษาการติดเชื้อจากสายพันธุ์ที่ดื้อยาหลายขนาน : รายงานการวิจัย. จุฬาลงกรณ์มหาวิทยาลัย, 2017. https://doi.org/10.58837/chula.res.2017.16.

Full text
Abstract:
ปัจจุบันมีรายงานการพบเชื้อ A. baumannii ที่ดื้อต่อยาในกลุ่ม carbapenems เพิ่มมากขึ้นทั่วโลก จึงมีการใช้ยาต้านจุลชีพหลายชนิดร่วมกันในการรักษาโรคติดเชื้อนี้ การศึกษานี้มีวัตถุประสงค์เพื่อศึกษาฤทธิ์ของยาต้านจุลชีพที่ใช้ร่วมกันต่อเชื้อ A. baumannii ที่ดื้อยาหลายขนานและศึกษาความสัมพันธ์ของฤทธิ์ของยาต้านจุลชีพที่ใช้ร่วมกันกับกลไกการดื้อยาของเชื้อ โดยทำการศึกษาในเชื้อ A. baumannii จำนวน 200 สายพันธุ์ที่แยกได้จากผู้ป่วยในปี พ.ศ. 2553-2558 พบว่า อัตราการดื้อยา imipenem, meropenem, cefotaxime, ceftriaxone, ceftazidime, cefepime amikacin, gentamicin, ciprofloxacin และ colistin คือ 86.5%, 87.5%, 87.5%, 87
APA, Harvard, Vancouver, ISO, and other styles
4

McCarthy, Noel, Eileen Taylor, Martin Maiden, et al. Enhanced molecular-based (MLST/whole genome) surveillance and source attribution of Campylobacter infections in the UK. Food Standards Agency, 2021. http://dx.doi.org/10.46756/sci.fsa.ksj135.

Full text
Abstract:
This human campylobacteriosis sentinel surveillance project was based at two sites in Oxfordshire and North East England chosen (i) to be representative of the English population on the Office for National Statistics urban-rural classification and (ii) to provide continuity with genetic surveillance started in Oxfordshire in October 2003. Between October 2015 and September 2018 epidemiological questionnaires and genome sequencing of isolates from human cases was accompanied by sampling and genome sequencing of isolates from possible food animal sources. The principal aim was to estimate the co
APA, Harvard, Vancouver, ISO, and other styles
5

D'Ambrozio, Jonathan A. Insights into the Enhanced in vivo Fitness of Neisseria gonorrhoeae Driven by a Fluoroquinolone Resistance-Conferring Mutant DNA Gyrase. Defense Technical Information Center, 2015. http://dx.doi.org/10.21236/ad1012700.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jorgensen, Frieda, John Rodgers, Daisy Duncan, Joanna Lawes, Charles Byrne, and Craig Swift. Levels and trends of antimicrobial resistance in Campylobacter spp. from chicken in the UK. Food Standards Agency, 2022. http://dx.doi.org/10.46756/sci.fsa.dud728.

Full text
Abstract:
Campylobacter spp. are the most common bacterial cause of foodborne illness in the UK, with chicken considered to be the most important vehicle of transmission for this organism. It is estimated there are 500,000 cases of campylobacteriosis in the UK annually, with Campylobacter jejuni (C. jejuni) and Campylobacter coli (C. coli) accounting for approximately 91% and 8 % of infections, respectively. Although severe infection in humans is uncommon, treatment is seldom needed for human infection but usually involves the administration of a macrolide (e.g., azithromycin) or a fluoroquinolone (e.g.
APA, Harvard, Vancouver, ISO, and other styles
7

Jorgensen, Frieda, Andre Charlett, Craig Swift, Anais Painset, and Nicolae Corcionivoschi. A survey of the levels of Campylobacter spp. contamination and prevalence of selected antimicrobial resistance determinants in fresh whole UK-produced chilled chickens at retail sale (non-major retailers). Food Standards Agency, 2021. http://dx.doi.org/10.46756/sci.fsa.xls618.

Full text
Abstract:
Campylobacter spp. are the most common bacterial cause of foodborne illness in the UK, with chicken considered to be the most important vehicle for this organism. The UK Food Standards Agency (FSA) agreed with industry to reduce Campylobacter spp. contamination in raw chicken and issued a target to reduce the prevalence of the most contaminated chickens (those with more than 1000 cfu per g chicken neck skin) to below 10 % at the end of the slaughter process, initially by 2016. To help monitor progress, a series of UK-wide surveys were undertaken to determine the levels of Campylobacter spp. on
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Fluoroquinolones' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography